Rheumatoid Arthritis VA Rating

Rheumatoid arthritis is rated under 38 CFR § 4.71a, diagnostic code 5002, and it does not work like the joint codes most veterans expect. DC 5002 runs on two parallel tracks. One track rates the disease as an active inflammatory process based on systemic impairment, exacerbation frequency, and constitutional symptoms. The other track rates the chronic residuals once the disease has gone inactive, based on limitation of motion or ankylosis of the joints it damaged. The single most important rule in the whole code is that you do not combine the two. You assign the higher.

That structure is where many RA claims go sideways. Rheumatoid arthritis is a chronic inflammatory disease. It classically causes symmetric swelling, in the same joints on both sides of the body, it flares and quiets down, and in about half of patients its antibodies show up in bloodwork years before the joint symptoms start. The rating examiner has to capture all of that: the antibody tests, the inflammation markers, the medication regimen, the exacerbation history, and the joint damage that's accumulated over time. When the exam captures only a snapshot of today's joint motion, the active-process rating collapses and the veteran gets rated as if the disease were a quiet case of osteoarthritis.

The Board data is consistent with how often that happens. Across 1,577 decided Board rulings on rheumatoid arthritis from 2021 to 2026, 14.0% were granted, 23.3% denied and 62.7% remanded. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. That is one of the highest remand shares of any condition I cover, 17.4 percentage points above the 45.3 percent across all decided Board rulings, and when the Board sent RA claims back, the most common reason was an inadequate VA exam or opinion.

This page covers the rheumatoid arthritis rating criteria under DC 5002, what each tier pays, the chronic-residual track, the C&P exam, documenting flares, how to prove service connection, conditions secondary to RA and its medications, and why VA denies RA claims.

TL;DR

• Rheumatoid arthritis is rated under 38 CFR § 4.71a, DC 5002, on two separate tracks: the disease as an active process, or the chronic residuals once it goes inactive.
• The active-process tiers run 100%, 60%, 40%, and 20%, driven by constitutional symptoms, weight loss and anemia, severity of health impairment, and the frequency of incapacitating exacerbations.
• The chronic-residual track is rated under DC 5003, which rates limitation of motion under the appropriate joint codes (ankylosis is rated under its own joint codes) and supplies minimum ratings when motion loss is noncompensable.
• The active-process rating and the residual rating are not combined. The rater assigns the higher of the two. That is the rule veterans most often need enforced.
• VA's arthritis questionnaire asks for antibody tests (RF, anti-CCP), inflammation markers (ESR, CRP), weight loss, anemia, and how often incapacitating exacerbations happen. Those facts drive the active-process rating.
• The medications used to control RA open a secondary chain under 38 CFR § 3.310: long-term corticosteroids are linked to cataracts, glaucoma, fractures and weight gain, and RA itself can involve the lungs, eyes and other organs.
• Across 1,577 decided Board rulings on rheumatoid arthritis from 2021 to 2026, 221 were granted (14.0%), 989 were remanded (62.7%), and 367 were denied (23.3%).
• That 62.7 percent remand share is one of the highest of any condition I cover, and the most common reason the Board sent RA claims back was an inadequate VA exam or opinion.

Rheumatoid arthritis VA rating criteria (DC 5002)

DC 5002 is titled "multi-joint arthritis (except post-traumatic and gout), 2 or more joints, as an active process," and Note (1) lists rheumatoid arthritis, psoriatic arthritis, and spondyloarthropathies as examples. Unlike the knee or shoulder codes, which rate a single mechanical impairment, DC 5002 has to account for a disease that moves through the body and changes over time. The regulation handles that by splitting the rating into two tracks.

The first track rates the disease while it is an active inflammatory process. This is the systemic rating. It looks at constitutional manifestations, the severity of impairment to overall health, and how often and how badly the veteran has incapacitating exacerbations. The active-process side has four compensable tiers, and each keys off systemic impairment and exacerbation frequency rather than a goniometer reading.

100% describes a veteran whose disease is both systemically active and disabling to the point of total incapacity. 60% has two paths: the constitutional path, weight loss and anemia producing severe health impairment, and the exacerbation path, four or more severely incapacitating flares a year, or fewer flares that run for prolonged periods. 40% turns on the words "definite impairment of health" and "objectively supported by examination findings." This tier requires the exam to actually document the objective findings, which is exactly where RA exams tend to fall short. 20% is the entry tier. It requires a well-established diagnosis and one or two exacerbations in a year.

The architecture of these tiers tells you what evidence drives the rating. The difference between 20%, 40%, and 60% on the active-process side is largely a question of how many incapacitating exacerbations the veteran has per year and how severely the disease impairs overall health. Those are facts that have to be documented over time, not measured in a single clinic visit.

The higher-of-two rule

The second track applies once the disease becomes inactive. At that point there's no active inflammation to rate, but the joints carry permanent damage. Note (2) to DC 5002 directs that chronic residuals be rated under DC 5003. Note (3) ties the two tracks together.

The ratings for the active process will not be combined with the residual ratings for limitation of motion, ankylosis, or diagnostic code 5003. Instead, assign the higher evaluation.

You do not add the active-process number to the residual number. You compare them and take the larger one. That matters in both directions. A veteran with severe joint damage but a currently quiet disease should be rated on residuals if that produces the higher figure. A veteran with relatively preserved motion but a severely active disease with frequent incapacitating flares should be rated on the active process. The rater's job is to evaluate both and pick the higher. The error I see most often is a rater evaluating only one track, usually the residual joint motion, and never reaching the active-process analysis at all. The DC 5002 reference sets out the code alongside this guide.

How much VA pays for rheumatoid arthritis

Using VA's rates effective December 1, 2025 (the 2026 rates), a veteran with no dependents is paid the following at each active-process tier. If you have other service-connected conditions, VA pays on the combined rating.

The jump from 40% to 60% is the one most worth documenting, because it turns on the number and length of severely incapacitating flares. A 60% rating on one disability also meets the schedular threshold for individual unemployability under 38 CFR § 4.16(a). If RA keeps you from substantially gainful work, the TDIU guide explains how VA pays at the 100% rate without a 100% schedular rating.

Chronic residuals: rating inactive rheumatoid arthritis (DC 5003)

When the rheumatoid disease becomes inactive, the active-process tiers stop applying because there is no active inflammation to rate. The residual track then rates the permanent joint damage the disease left behind.

Under Note (2), chronic residuals are rated under DC 5003, which uses limitation of motion of the affected joints under the appropriate diagnostic codes; ankylosis is rated under the joint codes. A veteran whose RA damaged the knees rates the residual knee limitation under the knee codes. RA that damaged the wrists rates under the wrist codes. RA that fused a joint rates the ankylosis. Section 4.27 uses this exact case as its example of a hyphenated code: rheumatoid arthritis rated as ankylosis of the lumbar spine is coded 5002-5240. Because RA classically affects the same joints on both sides, the residuals are often bilateral, which means the bilateral factor under 38 CFR § 4.26 often comes into play once the residuals are rated on paired extremities.

DC 5003 also supplies a floor. When limitation of motion in a joint is too small for a compensable rating under that joint's code, DC 5003 gives 10 percent for each major joint or group of minor joints with limited motion, confirmed by findings such as swelling, muscle spasm, or painful motion. With no limitation of motion at all, X-ray evidence of involvement of two or more major joints or two or more minor joint groups rates 10 percent, or 20 percent with occasional incapacitating exacerbations. The point is that inactive RA is not a zero. The joints carry the disease's history, and that history is ratable.

The reason the "assign the higher" rule matters so much is that a veteran can move between the two tracks over the life of the claim. During an active phase, the active-process rating may be higher. During a quiet phase with significant accumulated damage, the residual rating may be higher. A well-built record lets the rater see both and assign whichever is larger at any given time.

The rheumatoid arthritis C&P exam

This is the heart of the RA rating problem. An RA exam is not a range-of-motion exam with an autoimmune label. VA examines RA on its Non-Degenerative Arthritis Conditions questionnaire (updated August 22, 2024), which is built around the DC 5002 criteria. It asks whether the veteran has weight loss or anemia from the arthritis and whether either impairs health, how often non-incapacitating and incapacitating exacerbations happen, the total time incapacitated over the past 12 months, and whether there are constitutional manifestations. It also asks about involvement of other body systems and tells the examiner to complete the joint questionnaire for each affected joint.

A complete rheumatoid arthritis exam should capture the following.

• Antibody tests. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, which the questionnaire lists. They support the diagnosis, and a "well-established diagnosis," which the 20% tier requires, is built on this.
• Inflammation markers. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), also on the questionnaire. They measure inflammation and feed the disease activity scores rheumatologists use, which helps show whether the disease is active or quiet and so which track applies.
• Medication regimen. Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, often with corticosteroids, and biologic agents such as TNF inhibitors. The treatment a veteran is on is itself evidence of disease severity and activity, and it opens the secondary chain discussed below.
• Exacerbation history. How many incapacitating exacerbations the veteran has had in the past year, how long they lasted, and how severely they impaired function. This is the single most important fact for the active-process tiers and the one most often missing.
• Constitutional symptoms. Weight loss, anemia, fatigue, and overall impairment of health. The 60% and 100% tiers turn on these.
• Joint involvement on both sides. Which joints are affected, with range of motion and any ankylosis documented for the residual analysis.

When all of this is in the report, the rater has what's needed to evaluate both tracks and assign the higher. When the exam reduces RA to a single day's joint measurements, the active-process tiers have nothing to attach to, and the systemic disease gets rated as if it were mechanical joint wear.

Why RA exams get sent back so often

The problem is not random. It tracks the mismatch between how DC 5002 is written and how a routine joint exam is conducted. A standard musculoskeletal C&P exam is built to measure motion. It uses a goniometer, records flexion and extension, tests repetitive use, and notes pain. For a knee or a shoulder, that captures most of what the rating needs. For rheumatoid arthritis, it captures only the residual track and misses the active-process track entirely.

The active-process tiers ask questions a motion exam does not answer. How many incapacitating exacerbations per year? Is there weight loss and anemia producing severe impairment of health? Are the symptom combinations objectively supported by examination findings? An examiner who measures joint motion and writes "no flare observed today" has not addressed any of those questions.

The Board data points the same way. When the Board sent RA claims back, the most common reason was an inadequate VA exam or opinion. Most RA appeals at the Board are about service connection rather than the rating level, so many of those inadequate opinions are nexus opinions as well as rating exams. The Board section below shows how often each remand reason came up and how the appeals split by what they asked for.

Documenting rheumatoid arthritis flares

Because the active-process tiers turn on exacerbation frequency and severity, and because the C&P exam captures one day, the evidence the veteran builds outside the exam often decides the rating. The exam can confirm the diagnosis and current activity, but it cannot reconstruct a year of flares the examiner never saw.

The records that fill that gap are below.

• A symptom journal tracking each flare with dates, which joints were involved, how long the flare lasted, and whether the veteran could work or function during it. A symptom tracker makes this easier to keep.
• Documentation of incapacitating episodes: days bedridden, days unable to work, emergency or urgent care visits, steroid bursts prescribed to break a flare.
• Treatment records showing DMARD and biologic history, dose escalations, and switches between agents, which corroborate disease activity and severity.
• Lab trends over time showing ESR, CRP, RF, and anti-CCP values.
• Records of weight loss and anemia where present, which feed the 60% constitutional path.
• Statements from spouses, coworkers, or supervisors describing the veteran's function during active phases.

This is the RA analog of the flare-up documentation that drives knee and back claims. The difference is that for RA the exacerbation history is not a supplement to a motion rating, it is the substance of the active-process rating itself. Without it, the rater has no factual basis to reach 40% or 60%, and the claim defaults to the residual motion rating or to the 20% entry tier.

How to prove rheumatoid arthritis is service connected

Most rheumatoid arthritis appeals at the Board are about service connection, not the rating level. Every claim needs three things: a current diagnosis, evidence the disease started in service or within the presumptive window, and a medical link.

A current diagnosis. A rheumatologist's diagnosis supported by antibody tests and the clinical findings. Joint pain alone, or a diagnosis of osteoarthritis, does not establish RA.

Onset in service. Service treatment records showing joint swelling, morning stiffness, or pain in the small joints of the hands and wrists can matter even if no one named RA at the time; morning stiffness and hand and wrist swelling are among the classic classification criteria for RA. Statements from people who saw you struggle with stiffness or swelling in service fill gaps.

The one-year chronic disease rule. Arthritis is on the list of chronic diseases in 38 CFR § 3.309(a). Under § 3.307(a), if you served 90 days or more, arthritis that became manifest to a degree of 10 percent or more within one year after separation can be presumed service connected, even with no record of it in service. Under DC 5002, a well-established diagnosis with one or two exacerbations in that first year would meet the 20 percent level.

A medical opinion. When onset came later, a medical opinion has to explain why the RA is at least as likely as not related to service, and address the in-service record and any other explanation. When the Board denied RA service connection, the most common reason was that it found no link to service.

Conditions secondary to rheumatoid arthritis

Rheumatoid arthritis opens a wide secondary chain under 38 CFR § 3.310, and the medications used to control it are a major driver. Secondary service connection can be granted for a condition caused by a service-connected condition or aggravated by one (Allen v. Brown). Aggravation means the condition would be less severe but for the service-connected RA, and an opinion that addresses only causation and skips aggravation is inadequate (El-Amin v. Shinseki, 26 Vet. App. 136 (2013)).

Medication-driven secondaries. RA is often treated with methotrexate, frequently with corticosteroids, and with biologic agents. Long-term corticosteroid use is linked to cataracts, glaucoma, fractures, weight gain, and higher blood pressure. In a study of 1,066 RA patients, reported cataracts rose even below 5 mg of prednisone a day, and glaucoma and higher blood pressure above 7.5 mg a day. When a service-connected RA requires the medication, and the medication causes the new condition, the new condition can be claimed as secondary. The nexus opinion has to identify the drug, the documented exposure, and the mechanism. Related pages cover cataracts and glaucoma.

Organ and systemic involvement. RA is not limited to the joints. In a study of 788 patients in Spain, about a third had involvement outside the joints at some point, including rheumatoid nodules, Sjögren's syndrome, carpal tunnel syndrome, interstitial lung disease, and eye disease. VA's arthritis questionnaire asks the examiner about eye, skin, blood, lung, heart, nerve, kidney, digestive, and vascular involvement. Where the medical record documents RA-related involvement of another body system, that involvement can be service connected as part of, or secondary to, the rheumatoid disease.

Functional secondaries. As with any orthopedic condition that alters gait or use patterns, RA-damaged joints can drive compensatory stress and downstream musculoskeletal claims, though RA's tendency to affect both sides makes the one-sided compensation chains less typical than they are for a single damaged knee.

For any of these chains, the standard is the same. A bare assertion that "the condition is related to the veteran's RA" is not probative. The opinion has to identify the mechanism, address the time course, and account for other causes. A fully articulated medical opinion based on sound reasoning carries the chain. A conclusory one does not.

Why VA denies rheumatoid arthritis claims

Rheumatoid arthritis claims do worse at the Board than the average claim, mostly because so many are sent back rather than decided. Across 1,577 decided Board rulings on rheumatoid arthritis from 2021 to 2026, 14.0% were granted, 23.3% denied and 62.7% remanded. That grant rate is 10.7 points below the Board-wide 24.7 percent, and the remand share is one of the highest of any condition I cover.

When the Board denied RA service connection, the most common reason was no link to service, followed by no current diagnosis and then no in-service event. When it sent a claim back, the most common reason was an inadequate VA exam or opinion. The patterns behind those outcomes repeat.

No medical link to service. RA that was diagnosed years after discharge, with nothing in the service records and no opinion explaining a connection, is the most common denial. An opinion that ignores in-service joint complaints, or the one-year chronic disease rule, gives the Board nothing to weigh.

No current diagnosis, or the wrong one. The record shows joint pain or osteoarthritis but no rheumatologist's diagnosis supported by antibody tests and clinical findings.

The exam measures motion and never reaches the active process. The examiner runs a standard joint exam, records range of motion, and never documents exacerbation frequency, constitutional symptoms, or systemic disease activity. The rater is then stuck on the residual track and the active-process tiers go unaddressed.

No exacerbation history in the record. The active-process tiers turn on how many incapacitating flares the veteran has per year. When neither the exam nor the treatment records quantify the flares, the rater cannot reach 40% or 60% and defaults to the 20% entry tier or to residuals.

Antibody and inflammation labs missing or stale. RF, anti-CCP, ESR, and CRP support the diagnosis and help show whether the disease is active. Without current labs, the "well-established diagnosis" requirement at 20% can be questioned, and the active-versus-inactive determination that decides which track applies has no objective anchor.

Medication regimen not documented as evidence. The DMARD and biologic history is evidence of disease severity and the trigger for the medication-secondary chain. When the record does not lay out what the veteran is taking and why, the rater loses both a severity signal and a secondary-claim pathway.

Residuals undervalued during quiet phases. When the disease is inactive, raters sometimes treat the claim as resolved rather than rating the accumulated joint damage on the residual track. Inactive RA still leaves ratable limitation of motion and, in some joints, ankylosis.

Among RA claims the Board granted or denied, those with a private medical opinion in the record were granted far more often than RA claims overall, an association rather than proof of cause. The Board section below shows how often each denial and remand reason came up, and how the Board ruled when it relied on a favorable medical opinion, an opinion against the claim, or none.

Questions veterans ask about rheumatoid arthritis

What is the highest VA rating for rheumatoid arthritis?

100 percent, under DC 5002, when constitutional manifestations with active joint involvement are totally incapacitating. Below that, the active-process tiers are 60, 40 and 20 percent, and inactive RA is rated on its joint residuals instead.

Can VA rate rheumatoid arthritis as an active process and on joint damage at the same time?

No. Note (3) to DC 5002 says the active-process rating is not combined with ratings for limitation of motion, ankylosis or DC 5003. VA rates both ways and assigns whichever is higher.

Is rheumatoid arthritis a presumptive condition for VA?

Only through the one-year chronic disease rule. Arthritis is listed in 38 CFR § 3.309(a), so RA that reached 10 percent within a year after discharge can be presumed service connected. RA is not on the Agent Orange list in § 3.309(e) or the PACT Act burn pit list, so otherwise you need direct evidence or a medical opinion.

Does VA rate rheumatoid arthritis in each joint separately?

Only on the residual track. Inactive RA is rated on limitation of motion or ankylosis of each affected joint under that joint's code, and the bilateral factor in 38 CFR § 4.26 can add to the combined value when both arms or both legs have compensable ratings. The active-process rating is one rating for the whole disease.

Can conditions caused by RA medications be service connected?

Yes. Under 38 CFR § 3.310, a condition caused or made worse by the medication a service-connected RA requires, such as cataracts or glaucoma from long-term corticosteroids, can be service connected as secondary. You need a medical opinion that names the drug, your exposure, and how it caused or worsened the condition.

Bottom Line

Rheumatoid arthritis ratings are not a single joint number. DC 5002 runs on two tracks: the disease as an active inflammatory process, rated on constitutional symptoms and exacerbation frequency at 20%, 40%, 60%, and 100%, and the chronic residuals once the disease goes inactive, rated on limitation of motion or ankylosis of the damaged joints. You do not combine the tracks. You assign the higher. The exam is where RA claims most often go wrong. In Claim Raven's Board data, 62.7% of decided RA rulings were remanded, one of the highest shares of any condition I cover, and an inadequate VA exam or opinion was the most common reason. The cases that win document the disease as a system: antibody tests, inflammation markers, the medication regimen, and a real exacerbation history. Same disease, different paper trail, different outcome.

Related Conditions

Rheumatoid arthritis connects to several other orthopedic pages because the rating logic and proof problems overlap. Compare it with arthritis and gout, the other inflammatory and degenerative joint conditions, and with psoriatic arthritis, which DC 5002 rates the same way. RA residuals get rated on the joint pages, including knee and shoulder. Fibromyalgia shares the systemic, flare-driven evidence problem where a single exam fails to capture a year of symptoms. Veterans on long-term RA medications should review the secondary conditions tool before assuming the joint rating tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.71a, DC 5002 (multi-joint arthritis as an active process), including the active-process tiers and Notes (1) to (3) on covered conditions, chronic residuals and non-combination. Chronic residuals and minimum compensable involvement under DC 5003. Hyphenated codes from § 4.27. Bilateral factor from § 4.26. TDIU threshold from § 4.16. Chronic disease presumption from §§ 3.307(a)(3) and 3.309(a). Secondary service connection from § 3.310. Case law from Allen v. Brown on secondary aggravation and El-Amin v. Shinseki, 26 Vet. App. 136 (2013), on opinions that skip aggravation. Exam content from VA's Non-Degenerative Arthritis Conditions Disability Benefits Questionnaire (updated August 22, 2024). Compensation figures are VA's rates effective December 1, 2025 (the 2026 rates) for a veteran with no dependents.
• Medical sources: Nielen, "Specific autoantibodies precede the symptoms of rheumatoid arthritis," Arthritis and Rheumatism (2004); Arnett, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis," Arthritis and Rheumatism (1988); Aletaha, "Diagnosis and Management of Rheumatoid Arthritis: A Review," JAMA (2018); Huscher, "Dose-related patterns of glucocorticoid-induced side effects," Annals of the Rheumatic Diseases (2009); Curtis, "Population-based assessment of adverse events associated with long-term glucocorticoid use," Arthritis and Rheumatism (2006); Carmona, "Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity," Annals of the Rheumatic Diseases (2003).
• Board snapshot: Across 1,577 decided Board rulings on rheumatoid arthritis from 2021 to 2026, 14.0% were granted (including partial grants and mixed outcomes), 23.3% denied and 62.7% remanded. Dismissed, withdrawn and moot rulings are excluded. These are appealed claims, not your personal odds.
• Sample size: Board figures come from Claim Raven's read of every Board decision from 2021 to 2026 that it holds, 511,036 decisions containing 1,378,030 rulings, including 1,734 rulings on rheumatoid arthritis (1,577 decided). Among the decided rulings, outcomes ran 221 granted (14.0%), 989 remanded (62.7%), and 367 denied (23.3%). The remand share is one of the highest of any condition I cover. The data captures outcome by issue type rather than a per-tier (20%/40%/60%/100%) breakdown.
• Classification approach: Diagnostic code definitions drawn from the regulatory text. The two-track structure and the "assign the higher" rule follow DC 5002 directly. Denial and remand reasons are read from each ruling; one denial can rest on more than one reason. Secondary analysis follows § 3.310 and Allen v. Brown.
• Limitations:
• Compensation tiers reflect the rating percentages in DC 5002. Dollar figures adjust annually with COLA.
• The active-versus-inactive determination depends heavily on the quality and currency of the medical record, and application varies at the RO level.
• Selection bias: BVA-level patterns reflect cases that appealed. Most RA claims resolve at the RO level and aren't in any BVA dataset.
• The remand reasons show that an inadequate exam or opinion is the most common reason, but they do not separate rating exams from nexus opinions, so the link between DC 5002 exam gaps and the remand share is partly my reading of the decisions.
• The medication-secondary chains depend on documented exposure and a sound nexus opinion. They are pathways, not automatic grants.
• Private-opinion figures are associations, not causes.
• These observations reflect patterns from the regulatory text, case law, and BVA decisions. They are not predictions of individual outcomes.